Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?
Schizophrenia and autism spectrum disorders (ASD) are psychiatric neurodevelopmental disorders that cause high levels of functional disabilities. Also, the currently available therapies for these disorders are limited. Therefore, the search for treatments that could be beneficial for the altered cou...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.635763/full |
| _version_ | 1819295938026405888 |
|---|---|
| author | Cássio Morais Loss Cássio Morais Loss Lucas Teodoro Gabriela Doná Rodrigues Lucas Roberto Moreira Fernanda Fiel Peres Fernanda Fiel Peres Antonio Waldo Zuardi Antonio Waldo Zuardi José Alexandre Crippa José Alexandre Crippa Jaime Eduardo Cecilio Hallak Jaime Eduardo Cecilio Hallak Vanessa Costhek Abílio Vanessa Costhek Abílio |
| author_facet | Cássio Morais Loss Cássio Morais Loss Lucas Teodoro Gabriela Doná Rodrigues Lucas Roberto Moreira Fernanda Fiel Peres Fernanda Fiel Peres Antonio Waldo Zuardi Antonio Waldo Zuardi José Alexandre Crippa José Alexandre Crippa Jaime Eduardo Cecilio Hallak Jaime Eduardo Cecilio Hallak Vanessa Costhek Abílio Vanessa Costhek Abílio |
| author_sort | Cássio Morais Loss |
| collection | DOAJ |
| description | Schizophrenia and autism spectrum disorders (ASD) are psychiatric neurodevelopmental disorders that cause high levels of functional disabilities. Also, the currently available therapies for these disorders are limited. Therefore, the search for treatments that could be beneficial for the altered course of the neurodevelopment associated with these disorders is paramount. Preclinical and clinical evidence points to cannabidiol (CBD) as a promising strategy. In this review, we discuss clinical and preclinical studies on schizophrenia and ASD investigating the behavioral, molecular, and functional effects of chronic treatment with CBD (and with cannabidivarin for ASD) during neurodevelopment. In summary, the results point to CBD's beneficial potential for the progression of these disorders supporting further investigations to strengthen its use. |
| first_indexed | 2024-12-24T04:50:10Z |
| format | Article |
| id | doaj.art-d90042f610ea49438b3d2837551ba1b0 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-24T04:50:10Z |
| publishDate | 2021-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-d90042f610ea49438b3d2837551ba1b02022-12-21T17:14:35ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-02-011110.3389/fphar.2020.635763635763Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?Cássio Morais Loss0Cássio Morais Loss1Lucas Teodoro2Gabriela Doná Rodrigues3Lucas Roberto Moreira4Fernanda Fiel Peres5Fernanda Fiel Peres6Antonio Waldo Zuardi7Antonio Waldo Zuardi8José Alexandre Crippa9José Alexandre Crippa10Jaime Eduardo Cecilio Hallak11Jaime Eduardo Cecilio Hallak12Vanessa Costhek Abílio13Vanessa Costhek Abílio14Molecular and Behavioral Neuroscience Laboratory, Departamento de Farmacologia, Universidade Federal de São Paulo, São Paulo, BrazilNational Institute for Translational Medicine (INCT-TM), National Council for Scientific and Technological Development (CNPq/CAPES/FAPESP), Ribeirão Preto, BrazilMolecular and Behavioral Neuroscience Laboratory, Departamento de Farmacologia, Universidade Federal de São Paulo, São Paulo, BrazilMolecular and Behavioral Neuroscience Laboratory, Departamento de Farmacologia, Universidade Federal de São Paulo, São Paulo, BrazilMolecular and Behavioral Neuroscience Laboratory, Departamento de Farmacologia, Universidade Federal de São Paulo, São Paulo, BrazilMolecular and Behavioral Neuroscience Laboratory, Departamento de Farmacologia, Universidade Federal de São Paulo, São Paulo, BrazilNational Institute for Translational Medicine (INCT-TM), National Council for Scientific and Technological Development (CNPq/CAPES/FAPESP), Ribeirão Preto, BrazilNational Institute for Translational Medicine (INCT-TM), National Council for Scientific and Technological Development (CNPq/CAPES/FAPESP), Ribeirão Preto, BrazilDepartment of Neuroscience and Behavior, Ribeirão Preto Medical School, Universidade de São Paulo, Ribeirão Preto, BrazilNational Institute for Translational Medicine (INCT-TM), National Council for Scientific and Technological Development (CNPq/CAPES/FAPESP), Ribeirão Preto, BrazilDepartment of Neuroscience and Behavior, Ribeirão Preto Medical School, Universidade de São Paulo, Ribeirão Preto, BrazilNational Institute for Translational Medicine (INCT-TM), National Council for Scientific and Technological Development (CNPq/CAPES/FAPESP), Ribeirão Preto, BrazilDepartment of Neuroscience and Behavior, Ribeirão Preto Medical School, Universidade de São Paulo, Ribeirão Preto, BrazilMolecular and Behavioral Neuroscience Laboratory, Departamento de Farmacologia, Universidade Federal de São Paulo, São Paulo, BrazilNational Institute for Translational Medicine (INCT-TM), National Council for Scientific and Technological Development (CNPq/CAPES/FAPESP), Ribeirão Preto, BrazilSchizophrenia and autism spectrum disorders (ASD) are psychiatric neurodevelopmental disorders that cause high levels of functional disabilities. Also, the currently available therapies for these disorders are limited. Therefore, the search for treatments that could be beneficial for the altered course of the neurodevelopment associated with these disorders is paramount. Preclinical and clinical evidence points to cannabidiol (CBD) as a promising strategy. In this review, we discuss clinical and preclinical studies on schizophrenia and ASD investigating the behavioral, molecular, and functional effects of chronic treatment with CBD (and with cannabidivarin for ASD) during neurodevelopment. In summary, the results point to CBD's beneficial potential for the progression of these disorders supporting further investigations to strengthen its use.https://www.frontiersin.org/articles/10.3389/fphar.2020.635763/fullcannabidiolCannabidivarinschizophreniaAutismneurodevelopmental disordersProdrome |
| spellingShingle | Cássio Morais Loss Cássio Morais Loss Lucas Teodoro Gabriela Doná Rodrigues Lucas Roberto Moreira Fernanda Fiel Peres Fernanda Fiel Peres Antonio Waldo Zuardi Antonio Waldo Zuardi José Alexandre Crippa José Alexandre Crippa Jaime Eduardo Cecilio Hallak Jaime Eduardo Cecilio Hallak Vanessa Costhek Abílio Vanessa Costhek Abílio Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? Frontiers in Pharmacology cannabidiol Cannabidivarin schizophrenia Autism neurodevelopmental disorders Prodrome |
| title | Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? |
| title_full | Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? |
| title_fullStr | Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? |
| title_full_unstemmed | Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? |
| title_short | Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? |
| title_sort | is cannabidiol during neurodevelopment a promising therapy for schizophrenia and autism spectrum disorders |
| topic | cannabidiol Cannabidivarin schizophrenia Autism neurodevelopmental disorders Prodrome |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2020.635763/full |
| work_keys_str_mv | AT cassiomoraisloss iscannabidiolduringneurodevelopmentapromisingtherapyforschizophreniaandautismspectrumdisorders AT cassiomoraisloss iscannabidiolduringneurodevelopmentapromisingtherapyforschizophreniaandautismspectrumdisorders AT lucasteodoro iscannabidiolduringneurodevelopmentapromisingtherapyforschizophreniaandautismspectrumdisorders AT gabrieladonarodrigues iscannabidiolduringneurodevelopmentapromisingtherapyforschizophreniaandautismspectrumdisorders AT lucasrobertomoreira iscannabidiolduringneurodevelopmentapromisingtherapyforschizophreniaandautismspectrumdisorders AT fernandafielperes iscannabidiolduringneurodevelopmentapromisingtherapyforschizophreniaandautismspectrumdisorders AT fernandafielperes iscannabidiolduringneurodevelopmentapromisingtherapyforschizophreniaandautismspectrumdisorders AT antoniowaldozuardi iscannabidiolduringneurodevelopmentapromisingtherapyforschizophreniaandautismspectrumdisorders AT antoniowaldozuardi iscannabidiolduringneurodevelopmentapromisingtherapyforschizophreniaandautismspectrumdisorders AT josealexandrecrippa iscannabidiolduringneurodevelopmentapromisingtherapyforschizophreniaandautismspectrumdisorders AT josealexandrecrippa iscannabidiolduringneurodevelopmentapromisingtherapyforschizophreniaandautismspectrumdisorders AT jaimeeduardoceciliohallak iscannabidiolduringneurodevelopmentapromisingtherapyforschizophreniaandautismspectrumdisorders AT jaimeeduardoceciliohallak iscannabidiolduringneurodevelopmentapromisingtherapyforschizophreniaandautismspectrumdisorders AT vanessacosthekabilio iscannabidiolduringneurodevelopmentapromisingtherapyforschizophreniaandautismspectrumdisorders AT vanessacosthekabilio iscannabidiolduringneurodevelopmentapromisingtherapyforschizophreniaandautismspectrumdisorders |